News and Announcements
Strong interim results of CAVATAK in Phase 2 Trial
- Published July 19, 2013 10:42AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
19 July 2013, Sydney, Australia: Viralytics Limited (ASX:VLA, OTC:VRACY) today announced strong interim results from its Phase 2 clinical trial of CAVATAK™ treatment in late stage melanoma patients.
The interim data shows solid progress towards achieving the primary endpoint of the study and stregthens the evidence of the tolerability of CAVATAK™ in late stage melanoma patients.
Earlier today, Dr Robert Andtbacka, the lead study investigator from the Huntsman Cancer Institute in the USA, presented on the safety and investigator assessed efficacy data from the first 35 patients in the CALM study at the 8th World Congress of Melanoma, Hamburg, Germany.
To read the full ASX announcement, please download the document below.